

## PRE-MEETING SYMPOSIA – Saturday, May 31, 2008

### FULL DAY COURSES

8:00 am – 5:00 pm	Transplant Immunology for the Clinician
8:00 am – 5:00 pm	Clinical Updates
8:30 am – 5:00 pm	Transplant Nurse and Coordinator Course
8:00 am – 5:00 pm	Hepatitis C and Liver Transplantation
8:00 am – 5:30 pm	HRSA and OPTN: Current Issues and Initiatives
8:00 am – 5:30 pm	Updates for the Clinician-Scientist

### AFTERNOON HALF-DAY COURSES

1:30 pm – 5:30 pm	Pediatric Transplantation
2:00 pm – 5:30 pm	Infectious Disease



## FULL DAY SESSIONS

### 1. Transplant Immunology for the Clinician

#### Transplant Immunology I: Antigen Dependent Mechanisms

*Chair: James S. Allan, MD, Massachusetts General Hospital, Boston, MA*

8:00 am – 8:30 am	Alloimmunity and Antigen Processing <i>James S. Allan, MD Massachusetts General Hospital, Boston, MA</i>
8:30 am – 9:00 am	T-cell Activation <i>John Iacomini, PhD Brigham and Women's Hospital, Boston, MA</i>
9:00 am – 9:30 am	B-cell Activation <i>Anita S. Chong, MD University of Chicago, Chicago, IL</i>
9:30 am – 10:00 am	Alloantibodies: Early and Late Effects in Graft Injury <i>Robert B. Colvin, MD Harvard Medical School, Cambridge, MA</i>
10:00 am – 10:30 am	Coffee Break

#### Transplant Immunology II: Antigen Independent Mechanisms

*Chair: Roslyn B. Mannon, MD, NIDDK, National Institutes of Health, Bethesda, MD*

10:30 am – 11:00 am	Toll-like Receptors in Solid Organ Transplantation <i>Daniel Goldstein, MD Yale University School of Medicine, New Haven, CT</i>
11:00 am – 11:30 am	Chemokines and Cell Traffic <i>Jonathan S. Bromberg, MD, PhD Mt. Sinai School of Medicine, New York, NY</i>
11:30 am – 12:00 nn	Effector Mechanisms Leading to Graft Destruction <i>Richard N. Pierson III, MD University of Maryland, Baltimore, MD</i>
12:00 nn – 12:30 pm	Allograft Fibrosis: The Response to Inflammation <i>Roslyn B. Mannon, MD NIDDK, National Institutes of Health, Bethesda, MD</i>
12:30 pm – 1:30 pm	Lunch



## Transplant Immunology III: Regulation of the Alloimmune Response

*Chair: John Iacomini, PhD,  
Brigham and Women's Hospital, Boston, MA*

- 1:30 pm – 2:00 pm      Regulatory T Cells  
*James F. Markmann, MD, PhD  
Massachusetts General Hospital,  
Boston, MA*
- 2:00 pm – 2:30 pm      Co-stimulatory Pathways in Rejection  
and Tolerance  
*Mohamed Sayegh, MD  
Brigham and Women's Hospital,  
Boston, MA*
- 2:30 pm – 3:00 pm      Memory T Cell Responses  
*Christian P. Larsen, MD  
Emory University, Atlanta, GA*
- 3:00 pm – 3:30 pm      Coffee Break

## Transplant Immunology IV: Clinical Application of Basic Science

*Chair: Anthony M. Jevnikar, MD,  
London Health Sciences Center, London, Canada*

- 3:30 pm – 4:00 pm      Anti-donor Antibody Responses: Their  
Detection and Clinical Relevance  
*Peter Nickerson, MD  
Canadian Blood Services, Manitoba,  
Canada*
- 4:00 pm – 4:30 pm      Immunogenicity Across Organs: A  
Hierarchy of Responses  
*Douglas J. Norman, MD  
Oregon Health and Sciences University,  
Portland, OR*
- 4:30 pm – 5:00 pm      Tolerance – Are We Getting Close?  
*Robert Lechler, PhD, FRCP  
Guy's, King's and St. Thomas' School of  
Medicine, London, United Kingdom*





## 2. Clinical Updates

### Complications of Transplantation

*Chairs: Edward Cole, MD, Toronto General Hospital, Toronto, Canada and Jonah Odum, MD, PhD, MBA, National Institutes of Health, Bethesda, MD*

#### Malignancy

- 8:00 am – 8:30 am Defining the Risks of Post-transplant Malignancy  
*Bertram L. Kasiske, MD  
University of Minnesota,  
Minneapolis, MN*
- 8:30 am – 9:00 am Can EBV-Related Lymphoproliferative Disease Be Prevented?  
*Atul Humar, MD  
University of Alberta, Edmonton, Canada*
- 9:00 am – 9:30 am Role of TOR Inhibitors in Post-transplant Neoplasia  
*Barry Kahan, MD, PhD  
University of Texas Health Science Center, Houston, TX*

9:30 am – 10:00 am Break

#### Metabolic Issues in Transplantation

- 10:00 am – 10:30 am Effects of New Onset Diabetes Mellitus on Graft and Patient Outcomes  
*Edward Cole, MD  
Toronto General Hospital, Toronto, Canada*
- 10:30 am – 11:00 am Role of Hepatitis C in New Onset Diabetes Mellitus in Organ Recipients  
*Roy D. Bloom, MD  
University of Pennsylvania,  
Philadelphia, PA*
- 11:00 am – 11:30 am Should Immunosuppression be Changed in Patients with New Onset Diabetes Mellitus?  
*Alan Wilkinson, MD  
University of California, Los Angeles,  
Los Angeles, CA*
- 11:30 am – 12:00 pm Insulin Resistance – A Metabolic Pathway That Contributes to Chronic Liver Injury  
*Graeme MacDonald, PhD, MBBS  
The Princess Alexandra Hospital,  
Woolloongabba, Australia*
- 12:00 pm – 1:30 pm Lunch Break

### Update on Immunosuppression

*Chairs: Kenneth A. Newell, MD, PhD, Emory University, Atlanta, GA and Jeffrey S. Zaltzman, MD, St. Michael's Hospital, Toronto, Canada*

- 1:30 pm – 2:00 pm Choosing Patients for Desensitization Protocols  
*James M. Gloor, MD  
Mayo Clinic Rochester, Rochester, MN*
- 2:00 pm – 2:30 pm Pharmacoeconomics of Induction Antibody Therapy  
*Mark A. Schnitzler, PhD  
Saint Louis University School of Medicine, St. Louis, MO*
- 2:30 pm – 3:00 pm New Immunosuppressive Drugs in the Pipeline  
*Flavio Vincenti, MD  
University of California San Francisco, San Francisco, CA*
- 3:00 pm – 3:30 pm Break
- 3:30 pm – 4:00 pm Cellular Assays for Monitoring Immunosuppression  
*Adriana Zeevi, PhD  
University of Pittsburgh, Pittsburgh, PA*
- 4:00 pm – 4:30 pm Monitoring for Post-transplant Humoral Immunity  
*Anil Chandraker, MB, CHB, MRC  
Brigham and Women's Hospital, Boston, MA*
- 4:30 pm – 5:00 pm Defining a State of Operational Tolerance  
*Kenneth A. Newell, MD, PhD  
Emory University, Atlanta, GA*

# 3. Transplant Nurse and Coordinator Course

Co-sponsored by the International Transplant Nurses Society (ITNS), NATCO, The Organization for Transplant Professionals, and the International Society of Heart and Lung Transplantation (ISHLT)

**Chairs: Kathy Schwab, RN, BSN, Mayo Clinic Rochester, Rochester MN and Catherine Garvey, RN, BA, CCTC, University of Minnesota Medical Center – Fairview, Minneapolis, MN**

- 8:30 am – 9:15 am      Developing Relationships with Referring Physicians  
*Michael Petty, MD*  
*University of Minnesota Medical Center – Fairview, Minneapolis, MN*
- 9:15 am – 10:00 am    Defining the High-risk Transplant Recipient from a Psychosocial Point of View  
*Fabienne Dobbels, PhD*  
*Center for Health Services and Nursing Research, Katholieke Universiteit, Leuven, Belgium*
- 10:00 am – 10:15 am    Break
- 10:15 am – 11:00 am    Patient Education  
*Patricia Folk, RN, BSN, CCTC*  
*University of Pittsburgh Medical Center, Pittsburgh, PA*
- 11:00 am – 11:45 am    Quality Indicators/Dashboard  
*Marian O'Rourke, RN, CCTC*  
*Tulane University Hospital and Clinic, New Orleans, LA*
- 11:45 am – 12:30 pm    Life-Work Balance  
*Connie White-Williams, RN, MSN*  
*University of Alabama at Birmingham, Birmingham, AL*
- 12:30 pm – 1:30 pm    Lunch – On own

## Concurrent Sessions:

### Liver Transplant

*Chair: Patricia Folk, RN, BSN, CCTC, University of Pittsburgh Medical Center*

- 1:30 pm – 2:15 pm    Evaluation and Acceptance Criteria for the High-Risk Recipient  
*Dianne LaPointe Rudow, DrNP, CCTC*  
*New York Presbyterian Medical Center, New York, NY*
- 2:15 pm – 3:00 pm    Waitlist Management  
*Lindsay Arnott, RN, BS, CCTC*  
*Children's Medical Center Dallas, Dallas, TX*
- 3:00 pm – 3:15 pm    Break
- 3:15 pm – 4:00 pm    Risk Factors/Outcomes of Using

Extended Criteria Donors: Post-Operative Complications  
*Frank Van Gelder, RN, BSN, ECTC*  
*University Hospital Leuven Gasthuisberg, Belgium*

- 4:00 pm – 4:45 pm    Open-space Discussion  
*Dianne LaPointe Rudow, DrNP, CCTC;*  
*Lindsay Arnott, RN, BS, CCTC;*  
*Frank Van Gelder, RN, BSN, ECTC*

### Kidney Transplant

*Chair: Marian O'Rourke, RN, CCTC, Tulane University Hospital and Clinic, New Orleans, LA*

- 1:30 pm – 2:15 pm    Evaluation and Acceptance Criteria for the High-risk Recipient  
*Clare Whitaker, BSc*  
*The Royal London Hospital, London, United Kingdom*
- 2:15 pm – 3:00 pm    Waitlist Management  
*Catherine Garvey, RN, BA, CCTC*  
*University of Minnesota Medical Center-Fairview, Minneapolis, MN*
- 3:00 pm – 3:15 pm    Break
- 3:15 pm – 4:00 pm    Risk Factors/Outcomes of Using Extended Criteria Donors: Post-Operative Complications  
*Lynette Fix, RN, BA, CCTC*  
*Mayo Clinic Rochester, Rochester, MN*
- 4:00 pm – 4:45 pm    Open-space Discussion  
*Clare Whitaker, BSc;*  
*Catherine Garvey, RN, BA, CCTC;*  
*Lynette Fix, RN, BA, CCTC*

### Thoracic Transplant

*Chair: Michael Petty, MD, University of Minnesota Medical Center-Fairview, Minneapolis, MN*

- 1:30 pm – 2:15 pm    Evaluation and Acceptance Criteria for the High-Risk Recipient  
*Lori Coleman, RN, CPTC*  
*University of California, San Francisco, San Francisco, CA*
- 2:15 pm – 3:00 pm    Waitlist Management  
*Linda Ohler, RN, MSN, CCTC, FAAN*  
*Virginia Commonwealth University, Arlington, VA*
- 3:00 pm – 3:15 pm    Break
- 3:15 pm – 4:00 pm    Risk Factors/Outcomes of Using Extended Criteria Donors: Post-Operative Complications  
*Katherine Hoercher, RN*  
*Cleveland Clinic – Kaufman Center for Heart Failure, Cleveland, OH*
- 4:00 pm – 4:45 pm    Open-space Discussion  
*Lori Coleman, RN, CPTC;*  
*Linda Ohler, RN, MSN, CCTC, FAAN;*  
*Katherine Hoercher, RN*



## 4. Hepatitis C and Liver Transplantation

Co-sponsored with the International Liver Transplantation Society (ILTS)

### Background and Perspective

**Chairs:** Gary L. Davis, MD, Baylor University Medical Center, Dallas, TX and David C. Mulligan, MD, Mayo Clinic Hospital, Phoenix, AZ

- 8:00 am – 8:20 am Hepatitis C: Trends and Natural History  
*Edward Gane, MB/ChB, MD  
New Zealand Liver Transplant Unit,  
Auckland, New Zealand*
- 8:20 am – 8:40 am Current Pre-transplant Therapies for HCV Patients  
*James F. Trotter, MD  
University of Colorado, Denver, CO*
- 8:40 am – 9:10 am Molecular and Therapeutic Advances for Treatment of HCV  
*Michael R. Charlton, MD  
Mayo Clinic Rochester, Rochester, MN*
- 9:10 am – 9:30 am Hepatitis C as an Indication for Liver Transplantation  
*Gary A. Levy, MD  
Toronto General Hospital, Toronto, Canada*
- 9:30 am – 9:50 am Management of the Listed Patient  
*Gregory T. Everson, MD  
University of Colorado Health Science Center, Denver, CO*
- 9:50 am – 10:10 am Panel Discussion
- 10:10 am – 10:30 am Coffee Break

### HCV and Liver Transplantation

**Chairs:** Geoffrey W. McCaughan, PhD, MBBS, Royal Prince Alfred Hospital, Sydney, Australia and Alan N. Langnas, DO, University of Nebraska Medical Center, Omaha, NE

- 10:30 am – 10:50 am Outcomes of Transplantation for HCV Recipients  
*Shawn J. Pelletier, MD  
University of Michigan Health System,  
Ann Arbor, MI*
- 10:50 am – 11:10 am Treatment Strategies for HCV after Transplantation  
*Hugo E. Vargas, MD  
Mayo Clinic Hospital, Phoenix, AZ*
- 11:10 am – 11:30 am Managing Complications of Anti-viral Therapy  
*Sammy Saab, MD, MPN  
University of California, Los Angeles,  
Los Angeles, CA*

- 11:30 am – 11:50 am HCC in HCV Recipients  
*Jeffrey S. Crippin, MD  
Washington University School of  
Medicine, St Louis, MO*

- 11:50 am – 12:10 pm Panel Discussion

- 12:15 pm – 1:15 pm Lunch

### HCV Recurrence after Transplantation

**Chairs:** John J. Fung, MD, PhD, Cleveland Clinic Foundation, Cleveland, OH and Russell H. Wiesner, MD, Mayo Clinic Rochester, Rochester, MN

- 1:30 pm – 1:50 pm Virology of HCV Recurrence  
*Rajender Reddy, MD  
University of Pennsylvania, Philadelphia, PA*
- 1:50 pm – 2:10 pm Induction Therapy for Orthotopic Liver Transplantation in HCV  
*Michael R. Lucey, MD  
University of Wisconsin Hospital and Clinics, Madison, WI*
- 2:10 pm – 2:30 pm Ideal Immunosuppressive Protocols for HCV Recipients  
*Federico Villamil, MD  
Fundacion Favaloro, Buenos Aires, Argentina*
- 2:30 pm – 2:50 pm Retransplantation for HCV  
*Hugo R. Rosen, MD  
University of Colorado, Denver, CO*
- 2:50 pm – 3:10 pm Panel Discussion
- 3:10 pm – 3:30 pm Coffee Break

### Recurrence Risk Factors

**Chairs:** Kim M. Olthoff, MD, University of Pennsylvania Hospital, Philadelphia, PA and Robert S. Brown, Jr., MD, MPH, New York Presbyterian Hospital, New York, NY

- 3:30 pm – 3:50 pm Donor and Recipient Factors Implicated in Recurrence  
*R. Mark Ghobrial, MD, PhD  
University of California Los Angeles,  
Los Angeles, CA*
- 3:50 pm – 4:10 pm Should MELD Allocation be Changed to Reduce Recurrence Risk?  
*John R. Lake, MD  
University of Minnesota, Minneapolis, MN*
- 4:10 pm – 4:30 pm HCV Recurrence after Living Donation  
*Norah A. Terrault, MD, MPH  
University of California San Francisco,  
San Francisco, CA*
- 4:30 pm – 4:50 pm Panel Discussion

## 5. HRSA and OPTN: Current Issues and Initiatives

### Federal Oversight and Advancement of Organ Transplantation

*Chair: Virginia McBride, MPH, RN, CPTC, Health Resources and Services Administration, Rockville, MD*

- 8:00 am – 8:30 am Federal Oversight and Advancement of Transplantation: Statutory and Regulatory Basis  
*James F. Burdick, MD  
The Johns Hopkins Hospital, Baltimore, MD*
- 8:30 am – 9:00 am Solid Organ Allocation, Policymaking and Professional Oversight: The Organ Procurement and Transplantation Network  
*Christopher J. McLaughlin  
Health Resources and Services Administration, Rockville, MD*
- 9:00 am – 9:30 am Data Analyses to Support Solid Organ Policymaking: The Scientific Registry of Transplant Recipients  
*Gregory Fant, PhD  
U.S. Department of Health and Human Services, Rockville, MD*
- 9:30 am – 10:00 am Public and Professional Education Activities Advancing Organ Donation  
*Mary Ganikos, PhD  
Health Resources and Services Administration/HHS, Rockville, MD*
- 10:00 am – 10:30 am Break

### Organ Procurement and Transplant Network – Current Issues

*Chair: Timothy L. Pruett, MD, University of Virginia, Charlottesville, VA*

- 10:30 am – 11:30 am The OPTN Compliance Process  
*Robert S. D. Higgins, MD  
Rush University Medical Center, Chicago, IL*
- 11:00 am – 11:30 am DonorNet® – The First Year  
*Richard Hasz, MFS, CPTC  
Gift of Life Donor Program, Philadelphia, PA*
- 11:30 am – 12:00 nn Analyzing the Waitlist and Waitlist Mortality  
*Francis Delmonico, MD  
Massachusetts General Hospital, Boston, MA*
- 12:00 nn – 12:30 pm Progress Toward a New Kidney Allocation Schema  
*Mark D. Stegall, MD  
Mayo Clinic Rochester, Rochester, MN*
- 12:30 pm – 2:15 pm Lunch

## Maximizing Donor Management via Partnerships

*Chairs: Kevin O'Connor, MS, New England Organ Bank, Newton, MA and Charles Rosen, MD, Mayo Clinic Rochester, Rochester, MN*

- 2:15 pm – 2:45 pm Regional and Donation Service Areas Variation in Number of Organs Transplanted Per Donor  
*James F. Burdick, MD  
Health Resources and Services Administration, Rockville, MD*
- 2:45 pm – 3:15 pm Linking Donor Management Targets to Organs Transplanted Per Donor – The Impact of Donor Management “Bundles”  
*Diane Brockmeier, RN, BSN, MA  
Mid-America Transplant Services, St. Louis, MO*
- 3:15 pm – 3:45 pm Utilizing Advanced Clinical Practitioners to Implement Donor Management Protocols  
*Nader Habashi, MD  
University of Maryland, Baltimore, MD*
- 3:45 pm – 4:00 pm Break
- 4:00 pm – 4:30 pm Conducting Donation Service Area-Based Organ Specific “Mini-Collaboratives”  
*Susan Gunderson, MHA  
LifeSource, Minneapolis, MN*
- 4:30 pm – 5:00 pm Identifying the Elements of a Comprehensive Donor Management Protocol  
*David Powner, MD, FCCP, FCCM  
University of Texas, Houston, TX*
- 5:00 pm – 5:30 pm Sleeping With the Enemy: Effective Inter-program Conflict Resolution at Your Organ Procurement Organizations to Promote Donation  
*William Bry, MD  
California Pacific Medical Center, San Francisco, CA*





## 6. Updates for the Clinician-Scientist

### Highlights and What's New From Recent Clinical Trials

**Chair: Yolanda T. Becker, MD, University of Wisconsin Hospital and Clinics, Madison, WI**

- 8:00 am – 8:30 am      New Trends in Designing Trials and Reading the Literature: When Is Non-inferior Superior?  
*Herwig-Ulf Meier-Kriesche, MD  
University of Florida, Gainesville, FL*
- 8:30 am – 9:00 am      Highlights of What's New in Kidney Trials  
*Stephen Tomlanovich, MD  
University of California, San Francisco, San Francisco, CA*
- 9:00 am – 9:30 am      Highlights of What's New in Liver Trials  
*Paul Martin, MD  
Mt. Sinai School of Medicine, New York, NY*
- 9:30 am – 10:00 am    Highlights of What's New in Heart and Lung Trials  
*Richard N. Pierson III, MD  
University of Maryland, Baltimore, MD*
- 10:00 am – 10:30 am    Coffee Break

### Management of Clinical Problems Common to Solid Organ Transplants – Highlights of New Management Approaches

**Chair: Steven Paraskevas, MD, PhD, McGill University Health Centre, Montreal, Canada**

- 10:30 am – 11:00 am    Translating Drug Therapies to the Clinic: The Essentials of Pharmacokinetics to Pharmacogenomics  
*Gilbert Burckart, PharmD  
University of Southern California, Los Angeles, CA*
- 11:00 am – 11:30 am    Management of Renal Dysfunction in Non-renal Transplants with Renal Dysfunction – What's New?  
*Sandra M. Cockfield, MD  
University of Alberta, Edmonton, Canada*

11:30 am – 12:00 nn    The Major Viral Diseases and the Basics of their Management in Transplantation  
*Emily A. Blumberg, MD  
Hospital of the University of Pennsylvania, Philadelphia, PA*

12:00 nn– 12:30 pm    Standard Criteria to Extended Criteria to Donors after Cardiac Death: Managing with More Difficult Donors  
*Yolanda T. Becker, MD  
University of Wisconsin, Madison, WI*

12:30 pm – 1:30 pm    Lunch

### Updates in Topical Areas of Basic Research

**Chair: Xian Li, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA**

- 2:00 pm – 2:30 pm      Tolerance Induction: A Fresh Look at the Regulation of Regulatory Cells  
*Xian Li, MD, PhD  
Beth Israel Deaconess Medical Center, Boston, MA*
- 2:30 pm – 3:00 pm      Innate Immunity and Ischemia Reperfusion Injury – Can It Really be Modified in Transplantation?  
*Jerzy Kupiec-Weglinski, MD, PhD  
University of California, Los Angeles, Los Angeles, CA*
- 3:00 pm – 3:30 pm      Accommodation vs. Tolerance in Transplantation  
*Jeffrey L. Platt, MD  
Mayo Clinic Rochester, Rochester, MN*
- 3:30 pm – 4:00 pm      Break
- 4:00 pm – 4:30 pm      Xenotransplantation: A Myth, a Reality or Tool to Understand Allotransplantation?  
*Allan D. Kirk, MD, PhD  
Emory University, Atlanta, GA*
- 4:30 pm – 5:00 pm      What Should We be Doing for Chronic Rejection?  
*Stuart J. Knechtle, MD  
University of Wisconsin Hospital and Clinics, Madison, WI*
- 5:00 pm – 5:30 pm      Future Hot Areas for Basic Transplant Research  
*Roundtable Discussion with Session Speakers*

## HALF-DAY SESSIONS

### 7. Pediatric Transplantation

*Co-sponsored by the International Pediatric Transplantation Association (IPTA)*

#### Session I: Renal Dysfunction in Extra-renal Transplantation

*Chairs: Simon P. Horslen, MB, ChB, Children's Hospital and Regional Medical Center, Seattle, WA and Nancy D. Bridges, MD, NIAID, Rockville, MD*

- 1:30 pm – 1:50 pm      Quantifying the Problem  
*Brian Feingold, MD  
Children's Hospital of Pittsburgh,  
Pittsburgh, PA*
- 1:50 pm – 2:10 pm      Monitoring and Predicting Late Renal Dysfunction  
*Guido Filler, MD, PhD  
Children's Hospital, London Health  
Center, London, Canada*
- 2:10 pm – 2:30 pm      When and How to Prevent the Problem?  
*Vicky Ng, MD  
Hospital for Sick Children, Toronto,  
Canada*
- 2:30 pm – 2:50 pm      Late Kidney Transplantation after Prior Non-renal Transplantation  
*William Mahle, MD  
Emory University, Atlanta, GA*
- 2:50 pm – 3:30 pm      Roundtable Discussion
- 3:30 pm – 4:00 pm      Break

#### Session II: The HLA Sensitized Candidate and Recipient

*Chairs: Ruth A. McDonald, MD, Children's Hospital and Regional Health Center, Seattle, WA and J. Richard Thistlethwaite, Jr., MD, University of Chicago, Chicago, IL*

- 4:00 pm – 4:20 pm      Do Desensitization Protocols Really Work?  
*James M. Gloor, MD  
Mayo Clinic Rochester, Rochester, MN*
- 4:20 pm – 4:40 pm      Strategies for Transplanting Across a Positive Cross-Match  
*Anne Dipchand, MD, FRCPC  
The Hospital for Sick Children, Toronto,  
Canada*

- 4:40 pm – 5:00 pm      Why is Antibody Mediated Graft Damage not Universal with a Positive Cross-Match?  
*Steven A. Webber, MBChB  
Children's Hospital of Pittsburgh,  
Pittsburgh, PA*

- 5:00 pm – 5:30 pm      Roundtable Discussion

### 8. Infectious Disease

#### Practical Aspects of Transplant ID: A Case-based State-of-the-Art Update

*Chairs: Jay A. Fishman, MD, Massachusetts General Hospital, Boston, MA and Michael G. Ison, MD, Northwestern University, Chicago, IL*

- 2:00 pm – 2:30 pm      Donor-Derived Infection: State-of-the-Art  
*Jay A. Fishman, MD  
Massachusetts General Hospital,  
Boston, MA*
- 2:30 pm – 3:00 pm      Controversies in Management of BK Viremia  
*Hans H. Hirsch, MD, MSc  
Institute for Medical Microbiology,  
Basel, Switzerland*
- 3:00 pm – 3:30 pm      Cryptococcal Meningitis and CNS Infections in Transplant Patients  
*Nina Singh, MD  
Veterans Affairs Medical Center,  
Pittsburgh, PA*
- 3:30 pm – 4:00 pm      Break
- 4:00 pm – 4:30 pm      Technical Complications in Split Liver and Living Donor Liver Transplant  
*Shimul Shah, MD  
University of Massachusetts, Worcester, MA*
- 4:30 pm – 5:00 pm      Respiratory Virus Infection Post-transplant  
*Michael G. Ison, MD  
Northwestern University, Chicago, IL*
- 5:00 pm – 5:30 pm      Roundtable Discussion